Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade.

Autor:	Choi, Eun-Sun1, Oh, Sejun2, Jang, Boonsil2, Yu, Hyun-Ju2, Shin, Ji-Ae3, Cho, Nam-Pyo2, Yang, In-Hyoung2, Won, Dong-Hoon3, Kwon, Hye-Jeong3, Hong, Seong3, Cho, Sung-Dae3 efiwdsc@snu.ac.kr
Zdroj:	Cellular Oncology (2211-3428). Jun2017, Vol. 40 Issue 3, p235-246. 12p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu